Status:
COMPLETED
Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40+ years
Brief Summary
This study evaluates hospitalizations and mortality in patients with Chronic Obstructive Pulmonary Disease (COPD) before and after the implantation of a new COPD treatment plan (replacement of tiotrop...
Eligibility Criteria
Inclusion
- Patients older than 40 years of age at the time of hospital admission
- Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) according to the International Statistical Classification of Diseases and Related Health Problems Version 10 (ICD-10) established by the Health Care Protocol of the Health Secretariat of Federal District (SES/DF), with the following codes:
- J41.0 - Simple chronic bronchitis
- J41.1 - Mucopurulent chronic bronchitis
- J41.8 - Mixed simple and mucopurulent chronic bronchitis
- J42 - Unspecified chronic bronchitis
- J43.1 - Panlobular emphysema
- J43.2 - Centrilobular emphysema
- J43.8 - Other emphysema
- J43.9 - Emphysema, unspecified
- J44.0 - Chronic obstructive pulmonary disease with acute lower respiratory infection
- J44.1 - Chronic obstructive pulmonary disease with acute exacerbation, unspecified
- J44.8 - Other specified chronic obstructive pulmonary disease
- J44.9 - Chronic obstructive pulmonary disease, unspecified
Exclusion
- Patients younger than 40 yeas of age at the time of hospital admission
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2021
Estimated Enrollment :
3015000 Patients enrolled
Trial Details
Trial ID
NCT06053541
Start Date
April 1 2021
End Date
July 1 2021
Last Update
October 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Brasil
São Paulo, Brazil, 04794-000